Oxidative metabolism may be associated with negative symptoms in schizophrenia

References

• Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia: manifestations, incidence and course in different cultures. A world health organization ten-country study. Psychol Med Monogr Suppl. 1992;20:1–97.
   PubMedGoogle Scholar
• Yanik M, Vural H, Kocyigit A, et al. Is the arginine-nitric oxide pathway involved in the pathogenesis of schizophrenia? Neuropsychobiology. 2003;47(2):61–65.
   Web of Science ®Google Scholar
• Lohr JB. Oxygen radicals and neuropsychiatric illness. Some Speculations. Arch Gen Psychiatry. 1991;48(12):1097–1106.
   PubMed Web of Science ®Google Scholar
• Reddy RD, Yao JK. Free radical pathology in schizophrenia: a review. Prostaglandins Leukot Essent Fatty Acids. 1996;55(1–2):33–43.
   Web of Science ®Google Scholar
• Mahadik SP, Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res. 1996;19(1):1–17.
   PubMed Web of Science ®Google Scholar
• Yao JK, Reddy R, McElhinny LG, et al. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J Psychiatr Res. 1998;32(6):385–391.
   Web of Science ®Google Scholar
• Zhang XY, Zhou DF, Cao LY, et al. Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. Psychiatry Res. 2003;117(1):85–88.
   PubMed Web of Science ®Google Scholar
• McCreadie RG, MacDonald E, Wiles D, et al. The nithsdale schizophrenia surveys. XIV: Plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and in normal subjects. Br J Psychiatry. 1995;167(5):610–617.
   Google Scholar
• Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39(1):44–84.
   PubMed Web of Science ®Google Scholar
• Valko M, Rhodes CJ, Moncol J, et al. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006;160(1):1–40.
   PubMed Web of Science ®Google Scholar
• McGue M, Gottesman II. The genetic epidemiology of schizophrenia and the design of linkage studies. Eur Arch Psychiatry Clin Neurosci. 1991;240(3):174–181.
   Web of Science ®Google Scholar
• Savas HA, Gergerlioglu HS, Armutcu F, et al. Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: impact of past episodes. World J Biol Psychiatry. 2006;7(1):51–55.
   PubMed Web of Science ®Google Scholar
• Gergerlioglu HS, Savas HA, Bulbul F, et al. Changes in nitric oxide level and superoxide dismutase activity during antimanic treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(3):697–702.
   PubMed Web of Science ®Google Scholar
• Herken H, Gurel A, Selek S, et al. Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch Med Res. 2007;38(2):247–252.
   PubMed Web of Science ®Google Scholar
• Herken H, Akyol O, Yilmaz HR, et al. Nitric oxide, adenosine deaminase, xanthine oxidase and superoxide dismutase in patients with panic disorder: alterations by antidepressant treatment. Hum Psychopharmacol. 2006;21(1):53–59.
   PubMed Web of Science ®Google Scholar
• Sogut S, Zoroglu SS, Ozyurt H, et al. Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism. Clin Chim Acta. 2003;331(1–2):111–117.
   PubMed Web of Science ®Google Scholar
• Hoffer A, Osmond H, Smythies J. Schizophrenia; a new approach. II. Result of a year’s research. J Ment Sci. 1954;100(418):29–45.
   Web of Science ®Google Scholar
• Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet. 1994;344(8924):721–724.
   PubMed Web of Science ®Google Scholar
• Yao JK, Reddy RD, van Kammen DP. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs. 2001;15(4):287–310.
   PubMed Web of Science ®Google Scholar
• Reddy R, Keshavan M, Yao JK. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res. 2003;62(3):205–212.
   Web of Science ®Google Scholar
• Uranova NA, Casanova MF, DeVaughn NM, et al. Ultrastructural alterations of synaptic contacts and astrocytes in postmortem caudate nucleus of schizophrenic patients. Schizophr Res. 1996;22(1):81–83.
   Web of Science ®Google Scholar
• Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry. 1999;46(6):729–739.
   PubMed Web of Science ®Google Scholar
• Southorn PA, Powis G. Free radicals in medicine. I. Chemical nature and biologic reactions. Mayo Clin Proc. 1988;63(4):381–389.
   Web of Science ®Google Scholar
• Virit O, Altindag A, Yumru M, et al. A defect in the antioxidant defense system in schizophrenia. Neuropsychobiology. 2009;60(2):87–93.
   PubMed Web of Science ®Google Scholar
• Gama CS, Salvador M, Andreazza AC, et al. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(3):512–515.
   PubMed Web of Science ®Google Scholar
• JR S. Neurology and neuropathology of schizophrenia, in schizophrenia as a brain disease. New York: Oxford University Press; 1987.
   Google Scholar
• Weinberger DR. From neuropathology to neurodevelopment. Lancet. 1995;346(8974):552–557.
   Web of Science ®Google Scholar
• Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem. 2004;37(4):277–285.
   PubMed Web of Science ®Google Scholar
• Dawson VL, Dawson TM. Nitric oxide actions in neurochemistry. Neurochem Int. 1996;29(2):97–110.
   Web of Science ®Google Scholar
• Karson CN, Griffin WS, Mrak RE, et al. Nitric oxide synthase (NOS) in schizophrenia: increases in cerebellar vermis. Mol Chem Neuropathol. 1996;27(3):275–284.
   Google Scholar
• Akyol O, Herken H, Uz E, et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(5):995–1005.
   PubMed Web of Science ®Google Scholar
• Derin D, Yazici A, Erkoc S. The investigation of free radical metabolism and antioxidant defense systems elements in patients with schizophrenic disorder. Klinik Psikofarmakoloji Bulteni/Bull Clin Psychopharmacol. 2001;11(3):174–182. Turkish.
   Google Scholar
• Zoroglu SS, Herken H, Yurekli M, et al. The possible pathophysiological role of plasma nitric oxide and adrenomedullin in schizophrenia. J Psychiatr Res. 2002;36(5):309–315.
   PubMed Web of Science ®Google Scholar
• Zoroglu SS, Yurekli M, Meram I, et al. Pathophysiological role of nitric oxide and adrenomedullin in autism. Cell Biochem Funct. 2003;21(1):55–60.
   PubMed Web of Science ®Google Scholar
• Bulut M, Selek S, Gergerlioglu HS, et al. Malondialdehyde levels in adult attention-deficit hyperactivity disorder. J Psychiatry Neurosci. 2007;32(6):435–438.
   PubMed Web of Science ®Google Scholar
• Kanofsky JD, Sandyk R. Antioxidants in the treatment of schizophrenia. Int J Neurosci. 1991;62(1–2):97–100.
   Web of Science ®Google Scholar
• Mahadik SP, Evans D, Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25(3):463–493.
   PubMed Web of Science ®Google Scholar
• Selek S, Savas HA, Gergerlioglu HS, et al. The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J Affect Disord. 2008;107(1–3):89–94.
   PubMed Web of Science ®Google Scholar
• Savas HA, Herken H, Yurekli M, et al. Possible role of nitric oxide and adrenomedullin in bipolar affective disorder. Neuropsychobiology. 2002;45(2):57–61.
   PubMed Web of Science ®Google Scholar
• Yu YW, Chen TJ, Wang YC, et al. Association analysis for neuronal nitric oxide synthase gene polymorphism with major depression and fluoxetine response. Neuropsychobiology. 2003;47(3):137–140.
   Web of Science ®Google Scholar
• Akyol O, Zoroglu SS, Armutcu F, et al. Nitric oxide as a physiopathological factor in neuropsychiatric disorders. In Vivo. 2004;18(3):377–390.
   Web of Science ®Google Scholar
• Akyol O, Yanik M, Elyas H, et al. Association between Ala-9Val polymorphism of Mn-SOD gene and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(1):123–131.
   PubMed Web of Science ®Google Scholar
• Mahadik SP, Scheffer RE. Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins Leukot Essent Fatty Acids. 1996;55(1-2):45–54.
   PubMed Web of Science ®Google Scholar
• Herken H, Uz E, Ozyurt H, et al. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry. 2001;6(1):66–73.
   PubMed Web of Science ®Google Scholar
• Berg D, Youdim MB, Riederer P. Redox imbalance. Cell Tissue Res. 2004;318(1):201–213.
   Web of Science ®Google Scholar
• Albayrak Y, Unsal C, Beyazyuz M, et al. Reduced total antioxidant level and increased oxidative stress in patients with deficit schizophrenia: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:144–149.
   Web of Science ®Google Scholar
• Padurariu M, Ciobica A, Dobrin I, et al. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett. 2010;479(3):317–320.
   PubMed Web of Science ®Google Scholar
• Yao JK, Reddy R, McElhinny LG, et al. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res. 1998;32(1):1–8.
   Web of Science ®Google Scholar
• Selek S, Herken H, Bulut M, et al. Oxidative imbalance in obsessive compulsive disorder patients: a total evaluation of oxidant-antioxidant status. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):487–491.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Zhou DF, Shen YC, et al. Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia. Neuropharmacology. 2012;62(5–6):1928–1934.
   PubMed Web of Science ®Google Scholar
• Ustundag B, Atmaca M, Kirtas O, et al. Total antioxidant response in patients with schizophrenia. Psychiatry Clin Neurosci. 2006;60(4):458–464.
   Web of Science ®Google Scholar
• Aycicek A, Erel O, Kocyigit A. Decreased total antioxidant capacity and increased oxidative stress in passive smoker infants and their mothers. Pediatr Int. 2005;47(6):635–639.
   PubMed Web of Science ®Google Scholar
• Yao JK, Keshavan MS. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal. 2011;15(7):2011–2035.
   PubMed Web of Science ®Google Scholar
• Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs. 2003;17(1):47–62.
   PubMed Web of Science ®Google Scholar
• Kohen R, Nyska A. Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol Pathol. 2002;30(6):620–650.
   PubMed Web of Science ®Google Scholar
• Qing H, Xu H, Wei Z, et al. The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+-induced apoptosis. Eur J Neurosci. 2003;17(8):1563–1570.
   Web of Science ®Google Scholar
• Zhang XY, Zhou DF, Cao LY, et al. Blood superoxide dismutase level in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr Res. 2003;62(3):245–250.
   PubMed Web of Science ®Google Scholar
• Srivastava N, Barthwal MK, Dalal PK, et al. Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology (Berl). 2001;158(2):140–145.
   Web of Science ®Google Scholar
• Obata T. Dopamine efflux by MPTP and hydroxyl radical generation. J Neural Transm (Vienna). 2002;109(9):1159–1180.
   Web of Science ®Google Scholar
• Bulut M, Savas HA, Altindag A, et al. Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia. World J Biol Psychiatry. 2009;10(4 Pt 2):626–628.
   PubMed Web of Science ®Google Scholar
• Miller ER, Appel LJ, Jiang L, et al. Association between cigarette smoking and lipidperoxidation in a controlled feding study. Circulation. 1997;96(4):1097–1101.
   PubMed Web of Science ®Google Scholar
• Li XF, Zheng YL, Xiu MH, et al. Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):1064–1067.
   Web of Science ®Google Scholar
• Yao JK, Reddy R, Van Kammen DP. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res. 1998;80(1):29–39.
   PubMed Web of Science ®Google Scholar
• Nakano Y, Yoshimura R, Nakano H, et al. Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: a pilot study. Hum Psychopharmacol. 2010;25(2):139–144.
   PubMed Web of Science ®Google Scholar
• Minutolo G, Petralia A, Dipasquale S, et al. Nitric oxide in patients with schizophrenia: the relationship with the severity of illness and the antipsychotic treatment. Expert Opin Pharmacother. 2012;13(14):1989–1997.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Tan YL, Cao LY, et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res. 2006;81(2–3):291–300.
   PubMed Web of Science ®Google Scholar
• Taneli F, Pirildar S, Akdeniz F, et al. Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia. Arch Med Res. 2004;35(5):401–405.
   PubMed Web of Science ®Google Scholar